Pharma BD Deal Intelligence
Arrow Group was the foundational pivot that turned Watson into a genuine global generics platform, directly enabling the Actavis rebrand and the Actavis/Allergan roll-up era
Full analysis, sources & comparables →Watson goes global with $1.75B Arrow deal, gaining commercial presence in over 20 international markets and a robust pipeline of 40 expected approvals over…
FTC consent order required Watson to divest generic cabergoline to Impax and Arrow's Resolution subsidiary to a new entity to preserve generic competition in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$1.05B cash + ~$500M Watson stock + $200M zero-coupon preferred. Generics; FTC consent order Dec 2009. Source: Watson IR, BioSpace, BioWorld.
Arrow Group was the foundational pivot that turned Watson into a genuine global generics platform, directly enabling the Actavis rebrand and the Actavis/Allergan roll-up era
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group (this deal) | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2009 deals · Watson Pharmaceuticals (Actavis Inc.) deals